Fig. 1: Radiologic and biochemical responses after BPX-601 and rimiducid infusions in patients with mCRPC. | Nature Communications

Fig. 1: Radiologic and biochemical responses after BPX-601 and rimiducid infusions in patients with mCRPC.

From: PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial

Fig. 1

a Waterfall plot depicting maximum fold change in tumor target lesion (per RECIST 1.1) (open bars) and PSA (closed bars) for individual mCRPC patients (n = 9) treated in cohort 5B (orange) and 5C (purple). * indicates patients who received steroids during treatment. Horizontal dash lines indicate 30% decrease in tumor size (−30%) and PSA decrease of 50% (PSA50) and 90% (PSA90). b Spider plot showing the kinetics of PSA response per patient within the 1st month after BPX-601 cell infusion. c Computed tomography scans demonstrating tumor reduction in patient mCRPC-5B-3 following administration of BPX-601 cells and a single rimiducid infusion. Radiologic images were obtained before therapy and at day 42 after BPX-601 cells. The tumor site is indicated by the orange arrow. Source data are provided as a Source Data file.

Back to article page